50558-95-7

Upstream product

• 123-75-1 pyrrolidine 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 100-52-7 benzaldehyde 

Downstream Products

• 1396010-91-5 (R)-2-((R)-(benzylthio)( phenyl)methyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 
• 1379610-88-4 3-methoxy-7-phenyl-5,6,10,11-tetrahydro-benzo[h][1,3]thiazino[2,3-b]-quinazoline-9(7H)-one 
• 1379610-90-8 (E)-3-methoxy-10-(4-methylbenzylidene)-7-phenyl-7,10-dihydro-5H-benzo[h]thiazolo[2,3-b]quinazoline-9(6H)-one 
• 13723-99-4 3-(6-Methoxy-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-2,2-dimethyl-3-phenyl-propionic acid 
• 108826-49-9 perchlorate de dimethoxy-3,11 tetrahydro-5,6,8,9 phenyl-7 dibenzoxanthylium 

Relevant academic research and scientific papers

2-(3′,4′-Dimethoxybenzylidene)tetralone induces anti-breast cancer activity through microtubule stabilization and activation of reactive oxygen species

Breast cancer is a leading cause of women mortality worldwide. Diverse analogues of 2-benzylidene tetralone have been synthesized and evaluated for anti-cancer activity against a panel of cancer cell lines. Among these, compounds 13, 15 and 19 exhibited p

UV-light induced domino type reactions: Synthesis and photophysical properties of unreported nitrogen ring junction quinazolines

An expedient method for the synthesis of 5,6-dihydrobenzo[h][1,2,4]triazolo[5,1-b]quinazolines by UV light has been developed. Our aim was to synthesize various α, β-unsaturated carbonyl compounds and to further react them with different amines in DMF, in

Ionic liquid-mediated facile synthesis and antimicrobial study of thiazolo [2,3-b]benzo[h]quinazolines and thiazino[2,3-b] benzo-[h]quinazolines

8-Methoxy-4-phenyl-3,4,5,6-tetrahydrobenzo[h]quinazoline-2(1H)-thione, obtained by the condensation of 2-benzylidene-6-methoxy-3,4-dihydronapthalene- 1(2H)-one with thiourea, on reaction with chloroacetic acid and 3-chloropropanoic acid in the presence of the ionic liquid N-methylpyridinium tosylate furnishes 3-methoxy-7-phenyl-7,10-dihydro-5H- benzo[h]thiazolo[2,3-b] quinazoline-9(6H)-one and 3-methoxy-7-phenyl-5,6,10,11-tetrahydro- benzo[h][1,3]thiazino[2,3-b]quinazoline-9(7H)-one. Further, condensation of the thione with 1,2-dibromoethane and 1,3-dibromopropane yields 3-methoxy-7-phenyl- 6,7,9,10-tetrahydro-5 H-benzo[h]thiazolo[2,3-b]quinazoline and 3-methoxy-7-phenyl-5,6,7,9,10,11-hexahydrobenzo [h][1,3]thiazino[2,3-b] quinazoline respectively. Arylidene derivatives have been obtained by two routes. The structures of the cyclized compounds have been established on the basis of elemental analysis and spectroscopic data. The synthesized compounds were screened for antimicrobial activity. Some of the compounds showed promising antimicrobial activities. Copyright

Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4 ) antagonists

This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, and to a method of using such compounds as LTB4 antagonists. The compounds of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.

Tetrahydronaphthalene and tetrahydroquinoline compounds, their preparation and their use as leukotriene B4(LTB4) antagonists

This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.

BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS

The invention relates to novel benzopyran and other benzo-fused leukotriene B 4 (LTB 4) antagonists of formula I and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, and to a method of using such compounds as LBT. sub.4 antagonists. The compounds of the invention inhibit the action of LTB 4 and are therefore useful in the treatment of LTB 4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruitus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma and other conditions where marked neutrophil infiltration occurs. STR1

Etude de l'oxydation de tetrahydroisoquinoleinols-4 dimethoxyles en 6,7 ou 7,8, et sur la reactivite du carbonyle de la tetrahydroisoquinolone-4 dimethoxylee en 6,7

Preparation des tetrahydroisoquinoleinols-4 mentionnes ci-dessus, et etude de l'oxydation de ceux-ci au moyen de divers reactifs: oxydations chromiques, par les bromamides, le dimethylsulfoxide, la reaction d'Oppenauer.Seule cette derniere a conduit aux t